新型冠状病毒诱发的炎症后肺纤维化治疗新进展  

Progress in Treatment of Post Inflammatory Pulmonary Fibrosis Induced by SARS-CoV-2 Infection

作　　者：黄丽惠 舒娟[2] 陶会会 包海荣[2] HUANG Lihui;SHU Juan;TAO Huihui;BAO Hairong(First Clinical Medical College of Lanzhou University,Lanzhou 730000,China;Department of Geriatric Respiratory,the First Hospital of Lanzhou University,Lanzhou 730000,China)

机构地区：[1]兰州大学第一临床医学院,甘肃省兰州市730000 [2]兰州大学第一医院老年呼吸科,甘肃省兰州市730000

出　　处：《中国全科医学》2024年第32期4085-4092,共8页Chinese General Practice

基　　金：国家重点研发计划精准医学研究专项-呼吸系统疾病专病队列研究(2016YFC0901100);甘肃省重点研发计划(20YF2FA013)。

摘　　要：新型冠状病毒(SARS-CoV-2)感染属于全球重大突发公共卫生事件,对全球卫生系统造成重大威胁。SARS-CoV-2感染康复后部分患者长时间存在多种呼吸道症状,这被称为SARS-CoV-2感染急性期后遗症,SARSCoV-2感染后肺纤维化(PCPF)作为其中一种后遗症可不同程度影响患者的呼吸功能和生活质量。有关PCPF的治疗是目前研究的热点,本文就PCPF的治疗方法做一综述,旨在改善PCPF患者的预后。Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)infection is a major public health emergency in the world,which poses a major threat to the global health system.After rehabilitation from SARS-CoV-2 infection,some patients may experience multiple respiratory symptoms for a long time,which is called the acute sequelae of SARS-CoV-2 infection.Post-COVID-19 pulmonary fibrosis(PCPF)as one of them,can affect the respiratory function and quality of life of patients to varying degrees.Regarding the treatment of PCPF is a hot topic in current research,and this article provides a review of treatment methods for PCPF,aiming to improve the prognosis of PCPF patients.

关 键 词：新型冠状病毒 肺纤维化 新型冠状病毒感染后肺纤维化 治疗 综述 

分 类 号：R563.13[医药卫生—呼吸系统]